ARG098, a novel anti-human Fas antibody,suppresses synovial hyperplasia and prevents cartilage destruction in a severe combined immunodeficient-HuRAg mouse model |
| |
| Authors: | Noriko Odani-Kawabata Miwa Takai-Imamura Osamu Katsuta Hiroshi Nakamura Kusuki Nishioka Keiko Funahashi Tsukasa Matsubara Minoru Sasano Hiroyuki Aono |
| |
| Affiliation: | (1) Research & Development Center, Santen Pharmaceutical Co., Ltd., 8916-16 Takayama-cho, Ikoma-shi, Nara, Japan;(2) Institute of Medical Science, St. Marianna University School of Medicine, 2-16-1, Sugo, Miyamae-ku, Kawasaki-shi, Kanagawa, Japan;(3) Matsubara Mayflower Hospital, 944-25 Fujita, Katou-shi, Hyogo, Japan |
| |
| Abstract: | Background The anti-human Fas/APO-1/CD95 (Fas) mouse/human chimeric monoclonal IgM antibody ARG098 (ARG098) targets the human Fas molecule. The cytotoxic effects of ARG098 on cells isolated from RA patients, on normal cells in vitro, and on RA synovial tissue and cartilage in vivo using implanted rheumatoid tissues in an SCID mouse model (SCID-HuRAg) were investigated to examine the potential of ARG098 as a therapy for RA. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
